0000950123-11-055989.txt : 20110602 0000950123-11-055989.hdr.sgml : 20110602 20110602133053 ACCESSION NUMBER: 0000950123-11-055989 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110602 FILED AS OF DATE: 20110602 DATE AS OF CHANGE: 20110602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Grifols SA CENTRAL INDEX KEY: 0001438569 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35193 FILM NUMBER: 11887829 BUSINESS ADDRESS: STREET 1: 1585 BROADWAY STREET 2: SUITE 2376 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 212-969-3335 MAIL ADDRESS: STREET 1: 1585 BROADWAY STREET 2: SUITE 2376 CITY: NEW YORK STATE: NY ZIP: 10036 6-K 1 y91558e6vk.htm FORM 6-K e6vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month June 2011
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name into English)
 
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes o No þ
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes o No þ
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No þ
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.___________.
 
 

 

 

Grifols, S.A.
TABLE OF CONTENTS
         
Item   Sequential Page Number
 
    2  

 

Table of Contents

This is a translation of a Spanish language announcement filed with the CNMV. In case of
discrepancies, the Spanish version will prevail.
RELEVANT EVENT
In compliance with article 82 of the Financial Markets Legislation (Ley del Mercado de Valores), Grifols, S.A. (“Grifols”) informs that the operations relating to the acquisition of Talecris Biotherapeutics Holding Corp., (“Talecris”) have concluded, as described in the “Nota sobre Acciones” (Securities Note) filed with the Official Registrar of the “Comisión Nacional del Mercado de Valores” (National Securities Market Commission), on June 1st and in the “Documento de Registro” (Register Document) filed on January 21st, 2011.
The merger between Grifols Inc. and Talecris has been executed, and as a result Grifols has become the sole shareholder of Talecris owning 100% of its share capital.
The integration process has started with immediate effect.
Barcelona, June 2, 2011
     
 
Raimon Grifols Roura
   
Secretary of the Board of Directors
    

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
         
  Grifols, S.A.
 		  
  By:   /s/ David I. Bell    
    Name:   David I. Bell   
    Title:   Authorized Signatory   
 
Date: June 2, 2011